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• Primary, original studies (clinical 
trials/observational)
Exclusion:
• Review articles, editorials, 
commentaries, and articles with abstracts 
and titles not in English. 
• No specified date range
Databases:
Comprehensive Search Strategy:
• Two reviewers completed the search 
independently. Inclusion discrepancies 
adjudicated by a third author. 
Data Extraction: 
• Patient demographics, study design, methods, and relevant findings 
AMD
• Leading cause of blindness in 
developed countries
• Aging population:  ↑ life 
expectancy =  ↑ prevalence 
of geriatric eye conditions
Types of studies: 
• Randomized control trials- 8
• Non-randomized control trials-2
• Cross-sectional studies- 4
• Prospective case series- 1
• Prospective cohort- 1
Falls/mobility as.. 
• Primary outcome(s)- 2
• Secondary outcome(s)-
11
• Listed as anecdotal 
adverse event- 3
How outcomes assessed: 
Quality of life questionnaires (5)
Physical Functioning questionnaires (4)
In-Person tests (3)
Falls reporting (2)
Highlights from Three Sample Studies:  
Treatment improvement in mobility/fall rate: 
In RCT of vitamin A vs. placebo in AMD patients-
After 30 days, the vitamin A group had a ↑ score by 
5 points on the mobility subscale compared to 
placebo when controlling for confounders (P = 
0.0224) 
No treatment improvement in mobility/fall rate:
No clinically significant difference in mobility 
outcomes on quality of life scale between 
bevacizumab and ranibizumab and continuous vs. 
discontinuous treatment regimens (p = 0.74 & p = 
0.73) (anti-VEGF injections)
Mobility = not significantly associated with the 
subjective gain of vision clarity by photodynamic 
therapy after correction for confounders (p=0.53)
FALLS
• Costs U.S. healthcare system ≈ 
$50 billion/year
• Linked to poorer overall 
functioning, earlier admission 
to long-term care facilities
• Heterogeneous study designs, methods, and findings-
difficult to compare studies 
• Need standardized measurement tool(s) for assessing 
mobility and patient falls
• Ophthalmology= needs a broader focus of outcomes 
• Patient-centered vs. organ-centered
• Public health lens
What is the impact of age-related macular 
degeneration treatments on patient mobility and 
falls?
Interventions for AMD: 





*Major public health problems! Let’s take a public 
health lens: 
*Citations furnished upon request
